혈전 및 지혈 바이오마커 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 검사 장소별, 검사 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)

Thrombosis And Hemostasis Biomarkers Market Growth & Trends

The global thrombosis and hemostasis biomarkers market size is expected to reach USD 7.92 Billion by 2030, expanding at a CAGR of 5.90% from 2023 to 2030. The rapid growth of the market is attributable to factors such as the increasing prevalence of chronic diseases such as pancreatic cancer, the rise in the geriatric population, the growing demand for personalized medicines, and advancements in technology.

The thrombosis & hemostasis biomarkers industry has grown significantly in recent years, with changes in adoption patterns and the introduction of novel technologies. The increasing trend of adopting POC analyzers in the market is creating traction for small-sized analyzers. Increasing research on mini- and microdevices is anticipated to continue over the coming years. For instance, in June 2022, Dr. Arnold Lining Ju announced the development of a microdevice that can detect blood clots and can be used to detect early signs of a heart attack.

The prevalence of chronic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and pancreatic cancer is anticipated drive the need for thrombosis & hemostasis biomarkers to detect the probability of hemostasis. Chronic diseases have a tendency to damage blood vessels, leading to the formation of clots that can block blood flow and cause serious health complications, such as stroke & heart attack. For instance, pulmonary embolism (PE), is a serious medical condition that occurs in the legs and travels to the lung, obstructing blood flow.

As per American Lung Association, in January 2023, PE affected nearly 900,000 people in the U.S. and nearly 33% of the people affected by (DVT) or pulmonary embolism (PE) experience recurrence of PE in ten years. Therefore, high prevalence and significant repetition of cases will lead to an increase in the demand for thrombosis & hemostasis biomarkers.

Furthermore, key players operating in the market are focusing on different forms of strategic initiatives such as mergers and acquisitions to increase their respective position in the thrombosis & hemostasis biomarkers industry. For instance, in January 2023, Thermo Fisher Scientific, Inc., announced a partnership with AstraZeneca to manufacture a blood-based and solid tissue companion diagnostic test for Tagrisso. This was expected to propel the thrombosis and hemostasis biomarkers industry. Additionally, in May 2022, Quidel Corporation acquired Ortho Clinical Diagnostics for USD 6 billion. The new company was named QuidelOrtho. Through this acquisition, Quidel gained access to Ortho Clinical Diagnostics' biomarker tests portfolio.

Thrombosis And Hemostasis Biomarkers Market Report Highlights

• Reagents and consumables segment of the market held the largest revenue share in 2022 and is attributable to the heightened prevalence of bleeding and coagulation disorders in the global population
• Clinical laboratory tests led the overall market in 2022, owing to their ability to diagnose and identify abnormalities in the blood clotting process while processing a high volume of samples
• Post-thrombin (PT) test held the largest revenue share in 2022, attributable to the test quality which allows monitoring the effectiveness of anticoagulant medications
• Deep Vein Thrombosis (DVT) held the largest revenue share in 2022, owing to its high prevalence and the high mortality risk
• Diagnostic centers held the largest revenue share in 2022, attributable to the growing reliance of hospitals on diagnostic centers for testing and the presence of specialized equipment to provide faster test results
• North America dominated the market in 2022 which can be attributed to a significant prevalence of thrombosis and hemostasis disorders, along with access to advanced technology
• A few of the key market playersinclude bioMerieux SA; Abbott; Werfen; HORIBA Ltd.; Quidel Corporation; F. Hoffmann-La Roche Ltd.; Diazyme Laboratories, Inc.; Biomedica Diagnostics; Thermo Fisher Scientific, Inc.; Siemens Healthineers.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Product Segment
    • 1.1.1.2 Test Location Segment
    • 1.1.1.3 Test Type Segment
    • 1.1.1.4 Application Segment
    • 1.1.1.5 End-Use Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Product And Test Location Segment Snapshot
• 2.3 Test Type Segment Snapshot
• 2.4 Application And End Use Segment Snapshot
• 2.5 Competitive Landscape Snapshot

Chapter 3 Thrombosis & Hemostasis Biomarkers Market Variables, Trends, And Scope

• 3.1 Thrombosis & Hemostasis Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increasing Prevalence Of Chronic Diseases
    • 3.2.1.1.1 Incidence Data Of Pancreatic Cancer
    • 3.2.1.2 Growing Geriatric Population
    • 3.2.1.3 Increasing Demand For Personalized Medicine
    • 3.2.1.4 Advancements In Technology
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 High Cost Of Diagnostic Tests
    • 3.2.2.2 Complexity Of Thrombotic Events
• 3.3 Thrombosis & Hemostasis Biomarkers Market Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 Pestle Analysis

Chapter 4 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)

• 4.1 Thrombosis & Hemostasis Biomarkers Market: Product Movement Analysis
• 4.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Product (USD Million)
  • 4.2.1 Analyzers
  • 4.2.2 Reagents & Consumables

Chapter 5 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Location, 2018 - 2030 (USD Million)

• 5.1 Thrombosis & Hemostasis Biomarkers Market: Test Location Movement Analysis
• 5.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Location (USD Million)
  • 5.2.1 Clinical Laboratory Tests
  • 5.2.2 Point-Of-Care Tests

Chapter 6 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Type, 2018 - 2030 (USD Million)

• 6.1 Thrombosis & Hemostasis Biomarkers Market: Test Type Movement Analysis
• 6.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Type (USD Million)
  • 6.2.1 D-Dimer
  • 6.2.2 Anti-Thrombin Iii
  • 6.2.3 Plasminogen
  • 6.2.4 Fibrin/Fibrinogen
  • 6.2.5 Soluble Fibrin
  • 6.2.6 Selectins
  • 6.2.7 Factor Viii
  • 6.2.8 Pt
  • 6.2.9 Aptt
  • 6.2.10 Others

Chapter 7 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 7.1 Thrombosis & Hemostasis Biomarkers Market: Application Movement Analysis
• 7.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Application (USD Million)
  • 7.2.1 Deep Vein Thrombosis (Dvt)
  • 7.2.2 Pulmonary Embolism (Pe)
  • 7.2.3 Disseminated Intravascular Coagulation (Dic)
  • 7.2.4 Others

Chapter 8 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By End Use, 2018 - 2030 (USD Million)

• 8.1 Thrombosis & Hemostasis Biomarkers Market: End-Use Movement Analysis
• 8.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By End Use (USD Million)
  • 8.2.1 Hospitals & Clinics
  • 8.2.2 Academic & Research Institute
  • 8.2.3 Diagnostic Centers
  • 8.2.4 Others

Chapter 9 Thrombosis & Hemostasis Biomarkers Market: Regional Estimates And Trend Analysis, By Product, Test Location, Test Type, Application, & End-Use

• 9.1 Thrombosis & Hemostasis Market: Regional Outlook
• 9.2 North America
  • 9.2.1 North America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2 U.S.
    • 9.2.2.1 Key Country Dynamics
    • 9.2.2.2 Target Disease Prevalence
    • 9.2.2.3 U.S. Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2.4 Competitive Scenario
    • 9.2.2.5 Regulatory Framework
    • 9.2.2.6 Reimbursement Scenario
  • 9.2.3 Canada
    • 9.2.3.1 Key Country Dynamics
    • 9.2.3.2 Target Disease Prevalence
    • 9.2.3.3 Canada Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3.4 Competitive Scenario
    • 9.2.3.5 Regulatory Framework
    • 9.2.3.6 Reimbursement Scenario
• 9.3 Europe
  • 9.3.1 Europe Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2 Uk
    • 9.3.2.1 Key Country Dynamics
    • 9.3.2.2 Target Disease Prevalence
    • 9.3.2.3 Uk Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2.4 Competitive Scenario
    • 9.3.2.5 Regulatory Framework
    • 9.3.2.6 Reimbursement Scenario
  • 9.3.3 Germany
    • 9.3.3.1 Key Country Dynamics
    • 9.3.3.2 Target Disease Prevalence
    • 9.3.3.3 Germany Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3.4 Competitive Scenario
    • 9.3.3.5 Regulatory Framework
    • 9.3.3.6 Reimbursement Scenario
  • 9.3.4 France
    • 9.3.4.1 Key Country Dynamics
    • 9.3.4.2 Target Disease Prevalence
    • 9.3.4.3 France Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4.4 Competitive Scenario
    • 9.3.4.5 Regulatory Framework
    • 9.3.4.6 Reimbursement Scenario
  • 9.3.5 Spain
    • 9.3.5.1 Key Country Dynamics
    • 9.3.5.2 Target Disease Prevalence
    • 9.3.5.3 Spain Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5.4 Competitive Scenario
    • 9.3.5.5 Regulatory Framework
    • 9.3.5.6 Reimbursement Scenario
  • 9.3.6 Italy
    • 9.3.6.1 Key Country Dynamics
    • 9.3.6.2 Target Disease Prevalence
    • 9.3.6.3 Italy Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6.4 Competitive Scenario
    • 9.3.6.5 Regulatory Framework
    • 9.3.6.6 Reimbursement Scenario
  • 9.3.7 Denmark
    • 9.3.7.1 Key Country Dynamics
    • 9.3.7.2 Target Disease Prevalence
    • 9.3.7.3 Denmark Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7.4 Competitive Scenario
    • 9.3.7.5 Regulatory Framework
    • 9.3.7.6 Reimbursement Scenario
  • 9.3.8 Sweden
    • 9.3.8.1 Key Country Dynamics
    • 9.3.8.2 Target Disease Prevalence
    • 9.3.8.3 Sweden Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8.4 Competitive Scenario
    • 9.3.8.5 Regulatory Framework
    • 9.3.8.6 Reimbursement Scenario
  • 9.3.9 Norway
    • 9.3.9.1 Key Country Dynamics
    • 9.3.9.2 Target Disease Prevalence
    • 9.3.9.3 Norway Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9.4 Competitive Scenario
    • 9.3.9.5 Regulatory Framework
    • 9.3.9.6 Reimbursement Scenario
  • 9.3.10 Rest Of Europe
• 9.4 Asia Pacific
  • 9.4.1 Asia Pacific Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2 Japan
    • 9.4.2.1 Key Country Dynamics
    • 9.4.2.2 Death Rate In Japan
    • 9.4.2.3 Target Disease Prevalence
    • 9.4.2.4 Japan Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2.5 Competitive Scenario
    • 9.4.2.6 Regulatory Framework
    • 9.4.2.7 Reimbursement Scenario
  • 9.4.3 China
    • 9.4.3.1 Key Country Dynamics
    • 9.4.3.2 Target Disease Prevalence
    • 9.4.3.3 China Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3.4 Competitive Scenario
    • 9.4.3.5 Regulatory Framework
    • 9.4.3.6 Reimbursement Scenario
  • 9.4.4 India
    • 9.4.4.1 Key Country Dynamics
    • 9.4.4.2 Target Disease Prevalence
    • 9.4.4.3 India Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4.4 Competitive Scenario'
    • 9.4.4.5 Regulatory Framework
    • 9.4.4.6 Reimbursement Scenario
  • 9.4.5 South Korea
    • 9.4.5.1 Key Country Dynamics
    • 9.4.5.2 Target Disease Prevalence
    • 9.4.5.3 South Korea Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5.4 Competitive Scenario
    • 9.4.5.5 Regulatory Framework
    • 9.4.5.6 Reimbursement Scenario
  • 9.4.6 Australia
    • 9.4.6.1 Key Country Dynamics
    • 9.4.6.2 Target Disease Prevalence
    • 9.4.6.3 Australia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6.4 Competitive Scenario
    • 9.4.6.5 Regulatory Framework
    • 9.4.6.6 Reimbursement Scenario
  • 9.4.7 Thailand
    • 9.4.7.1 Key Country Dynamics
    • 9.4.7.2 Target Disease Prevalence
    • 9.4.7.3 Thailand Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7.4 Competitive Scenario
    • 9.4.7.5 Regulatory Framework
    • 9.4.7.6 Reimbursement Scenario
  • 9.4.8 Rest Of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Latin America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2 Brazil
    • 9.5.2.1 Key Country Dynamics
    • 9.5.2.2 Brazil Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2.3 Target Disease Prevalence
    • 9.5.2.4 Competitive Scenario
    • 9.5.2.5 Regulatory Framework
    • 9.5.2.6 Reimbursement Scenario
  • 9.5.3 Mexico
    • 9.5.3.1 Key Country Dynamics
    • 9.5.3.2 Target Disease Prevalence
    • 9.5.3.3 Mexico Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3.4 Competitive Scenario
    • 9.5.3.5 Regulatory Framework
    • 9.5.3.6 Reimbursement Scenario
  • 9.5.4 Argentina
    • 9.5.4.1 Key Country Dynamics
    • 9.5.4.2 Target Disease Prevalence
    • 9.5.4.3 Argentina Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4.4 Competitive Scenario
    • 9.5.4.5 Regulatory Framework
    • 9.5.4.6 Reimbursement Scenario
  • 9.5.5 Rest Of Latin America
• 9.6 MEA
  • 9.6.1 MEA Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2 South Africa
    • 9.6.2.1 Key Country Dynamics
    • 9.6.2.2 Target Disease Prevalence
    • 9.6.2.3 South Africa Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2.4 Competitive Scenario
    • 9.6.2.5 Regulatory Framework
    • 9.6.2.6 Reimbursement Scenario
  • 9.6.3 Saudi Arabia
    • 9.6.3.1 Key Country Dynamics
    • 9.6.3.2 Target Disease Prevalence
    • 9.6.3.3 Saudi Arabia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3.4 Competitive Scenario
    • 9.6.3.5 Regulatory Framework
    • 9.6.3.6 Reimbursement Scenario
  • 9.6.4 UAE
    • 9.6.4.1 Key Country Dynamics
    • 9.6.4.2 Target Disease Prevalence
    • 9.6.4.3 Uae Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4.4 Competitive Scenario
    • 9.6.4.5 Regulatory Framework
    • 9.6.4.6 Reimbursement Scenario
  • 9.6.5 Kuwait
    • 9.6.5.1 Key Country Dynamics
    • 9.6.5.2 Target Disease Prevalence
    • 9.6.5.3 Kuwait Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5.4 Competitive Scenario
    • 9.6.5.5 Regulatory Framework
    • 9.6.5.6 Reimbursement Scenario
  • 9.6.6 Rest Of Mea

Chapter 10 Competitive Landscape

• 10.1 Company Categorization
• 10.2 Strategy Mapping
  • 10.2.1 New Product Launch
  • 10.2.2 Partnerships
  • 10.2.3 Acquisition
  • 10.2.4 Collaboration
  • 10.2.5 Funding
• 10.3 Key Company Market Share Analysis, 2022
• 10.4 Company Profiles
  • 10.4.1 Thermo Fisher Scientific, Inc.
    • 10.4.1.1 Company Overview
    • 10.4.1.2 Financial Performance
    • 10.4.1.3 Product Benchmarking
    • 10.4.1.4 Strategic Initiatives
  • 10.4.2 F. Hoffmann-La Roche Ltd.
    • 10.4.2.1 Company Overview
    • 10.4.2.2 Financial Performance
    • 10.4.2.3 Product Benchmarking
    • 10.4.2.4 Strategic Initiatives
  • 10.4.3 Siemens Healthineers
    • 10.4.3.1 Company Overview
    • 10.4.3.2 Financial Performance
    • 10.4.3.3 Product Benchmarking
    • 10.4.3.4 Strategic Initiatives
  • 10.4.4 Abbott
    • 10.4.4.1 Company Overview
    • 10.4.4.2 Financial Performance
    • 10.4.4.3 Product Benchmarking
    • 10.4.4.4 Strategic Initiatives
  • 10.4.5 BioMerieux SA
    • 10.4.5.1 Company Overview
    • 10.4.5.2 Financial Performance
    • 10.4.5.3 Product Benchmarking
    • 10.4.5.4 Strategic Initiative
  • 10.4.6 Werfen
    • 10.4.6.1 Company Overview
    • 10.4.6.2 Financial Performance
    • 10.4.6.3 Product Benchmarking
    • 10.4.6.4 Strategic Initiatives
  • 10.4.7 HORIBA Ltd.
    • 10.4.7.1 Company Overview
    • 10.4.7.2 Financial Performance
    • 10.4.7.3 Product Benchmarking
    • 10.4.7.4 Strategic Initiatives
  • 10.4.8 Quidel Corporation
    • 10.4.8.1 Company Overview
    • 10.4.8.2 Financial Performance
    • 10.4.8.3 Product Benchmarking
    • 10.4.8.4 Strategic Initiatives
  • 10.4.9 Diazyme Laboratories, Inc.
    • 10.4.9.1 Company Overview
    • 10.4.9.2 Financial Performance
    • 10.4.9.3 Product Benchmarking
    • 10.4.9.4 Strategic Initiatives
  • 10.4.10 Biomedica Diagnostics
    • 10.4.10.1 Company Overview
    • 10.4.10.2 Financial Performance
    • 10.4.10.3 Product Benchmarking
    • 10.4.10.4 Strategic Initiatives

Chapter 11 Conclusion